Cyxone Inks Api Deal With European Cdmo
Sweden-Based Cyxone, A Developer Of Therapies For Diseases Such As Rheumatoid Arthritis And Multiple Sclerosis As Well As Treatments For Virally Induced Acute Respiratory Disorders, Has Engaged A Major European Contract Development And Manufacturing Organization ( Cdmo ) For The Scale-Up And Production Of The Active Ingredient Of Its Drug Candidate T20K. The Production Will Be Performed In Accordance With Good Manufacturing Practice ( Gmp ), Exploring A Brand-New Manufacturing Method. The Collaboration Will Initially Cover Method Development And Later Supply Material For Use In Non-Clinical And Clinical Development Activities.Cyxone Is Developing T20K, A Peptide Aimed For The Treatment Of Multiple Sclerosis (Ms). Preclinical Data Indicate That The Drug Candidate Prevents Disease Progression In A Model System And Therefore Shows Potential To Slow Or Prevent Disease Progression Including Preventing The Demyelination Which Causes The Symptoms Of Ms.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!